Clinical Investigation of a Toothpaste Containing Stannous Fluoride as Compared to Colgate Fluoride Toothpaste

Overview

The objective of this study is to evaluate the clinical efficacy of a toothpaste containing stannous fluoride as compared to Colgate Fluoride Toothpaste in reducing plaque and gingivitis – a three- month study.

Full Title of Study: “Clinical Investigation of a Toothpaste Containing Stannous Fluoride as Compared to Colgate Fluoride Toothpaste in Reducing Plaque and Gingivitis – a Three Month Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 6, 2019

Detailed Description

This was a 6-month, randomized, single-center, parallel group, double-blinded, clinical research study to assess the clinical efficacy of two toothpastes containing stannous fluoride (SnHW and CPH) as compared to Regular Fluoride Toothpaste on the reduction of established dental plaque and gingivitis in adults.

Interventions

  • Drug: Colgate Total SF
    • 1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
  • Drug: Colgate Cavity Protection toothpaste
    • 0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.

Arms, Groups and Cohorts

  • Sham Comparator: Fluoride Control
    • Colgate Cavity Protection 0.76% as Na MFP Toothpaste
  • Active Comparator: Colgate Total SF
    • Colgate Total Clean Mint White Paste 1100 ppm F Toothpaste

Clinical Trial Outcome Measures

Primary Measures

  • Gingivitis Scores
    • Time Frame: Baseline
    • Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)
  • Gingivitis Scores
    • Time Frame: 3 months
    • Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)
  • Dental Plaque Score
    • Time Frame: Baseline
    • Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth)
  • Dental Plaque Score
    • Time Frame: 3 months
    • Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth)

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects, ages 18-70, inclusive. – Availability for the six-month duration ofthe clinical research study. – Good general health. – Minimum of 20 uncrowned permanent natural teeth (excluding third molars). – Initial gingivitis index of at least 1.0 as determined by the use of the Loe and Silness Gingival Index. – Initial plaque index of at least 1.5 as determined by the use of the Quigley and Hein °Plaque Index (Turesky Modification). – Signed Informed Consent Form. Exclusion Criteria:

  • Presence of partial denture. – Presence of partial removable dentures. – Tumor(s) of the soft or hard tissues of the oral cavity. – Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). – Five or more carious lesions requiring immediate restorative treatment. – Antibiotic use any time during the one month prior to entry into the study. – Participation in any other clinical study or test panel within the one month prior to entry into the study. – Dental prophylaxis during the past two weeks prior to baseline examinations. – History of allergies to oral care/personal care consumer products or their ingredients. – On any prescription medicines that might interfere with the study outcome. – An existing medical condition which prohibits eating or drinking for periods up to 4 hours. – History of alcohol or drug abuse. – Pregnant or lactating subjects.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Colgate Palmolive
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yun Po Zhang, Doctoral, Study Director, Colgate Palmolive

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.